Biosimilar Data Promotion May Be Easier Under Amarin Court Ruling
This article was originally published in The Pink Sheet Daily
Executive Summary
Companies may have a First Amendment right to promote their analytical and clinical data that do not appear in biosimilar product labeling, Hunton & Williams attorney Bradshaw says.